Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
about
Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVSImpact of Diet-Induced Obesity and Testosterone Deficiency on the Cardiovascular System: A Novel Rodent Model Representative of Males with Testosterone-Deficient Metabolic Syndrome (TDMetS)Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.Sildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells.Advances in targeting cyclic nucleotide phosphodiesterasesCyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.Effects of sildenafil on the gastrocnemius and cardiac muscles of rats in a model of prolonged moderate exercise training.PDE5 inhibitors as therapeutics for heart disease, diabetes and cancerImpact of Mitochondrial Ca2+-Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats.Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathwaysPhosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsThe cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.Sildenafil for noncompaction cardiomyopathy treatment in a child: case report.Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.Phosphodiesterase type 5 and cancers: progress and challenges.Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System.
P2860
Q27021649-31895AAB-AD6F-4E7A-9C3B-860C84F66EDBQ27318055-F72BBE53-5729-417B-B738-1F9FA244A2ECQ30462352-AADCBE21-1DF9-4EC0-AE23-9B0EC7ED9EC2Q33744352-E28B3AD5-F110-43B5-9684-5FC199844109Q34139490-1C1D7DDA-F41B-4003-B0E7-52A2D09A0FE0Q34765802-7009B788-1CEC-4ED5-AF15-5927B8A4C27FQ34905015-4CB05D63-F294-4E51-BCC6-FD19CF847608Q35827798-AD8F42CC-4137-4B2F-A4F1-3FED32706CE8Q35869812-4A9A59AC-1012-4BEE-8951-28AD6FE2C97DQ36366419-D74E6F09-D2E6-4F51-A0B6-F33EA6BB6243Q36460566-09924819-509C-4AC3-8E47-2DBE03243E7EQ38258238-AEA88F88-AA5C-40D7-A92B-03CADAE5C5DAQ38762791-29933A1D-A7EA-45A1-9EF4-D7C9A0D2F4C9Q41819549-631F7C6C-3F27-4358-A6FA-238269FD7AD8Q47171803-B7219E20-FC2F-4716-BD26-209F09B2FD4DQ52809588-129B5C46-D54D-4D08-8410-93C1D701CE8B
P2860
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
@ast
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
@en
type
label
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
@ast
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
@en
prefLabel
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
@ast
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
@en
P2093
P2860
P1476
Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases
@en
P2093
Fadi N Salloum
Rakesh C Kukreja
Ramzi A Ockaili
Saisudha Koka
P2860
P577
2011-01-01T00:00:00Z